Cresco Labs (CRLBF) Total Current Liabilities (2019 - 2026)
Cresco Labs' (CRLBF) quarterly Total Current Liabilities came in at $98.2 million in Q1 2026, down 13.27% YoY from $113.2 million in Q1 2025, and down 2.0% on a QoQ basis from $100.2 million in Q4 2025.
Cresco Labs (CRLBF) Total Current Liabilities (2019 - 2026) Analysis & Trends
Cresco Labs (CRLBF) has 8 years of Total Current Liabilities data on file, last reported at $98.2 million in Q1 2026.
- Quarterly Total Current Liabilities fell 13.27% year-over-year to $98.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $98.2 million (down 13.27% YoY) and the FY2025 annual result came in at $100.2 million, up 6.19% from the prior year.
- Total Current Liabilities declined to $98.2 million in Q1 2026, from $100.2 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $331.2 million in Q1 2022 to a low of $94.3 million in Q4 2024.
- A 5-year average of $186.3 million and a median of $200.2 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities advanced 29.31% — and 2024, when it plunged 52.89%.
- Tracing CRLBF's Total Current Liabilities over 5 years: stood at $255.9 million in 2022, then fell by 21.74% to $200.2 million in 2023, then sank by 52.89% to $94.3 million in 2024, then climbed by 6.19% to $100.2 million in 2025, then slipped by 2.0% to $98.2 million in 2026.
- The last three Total Current Liabilities figures came in at $98.2 million (Q1 2026), $100.2 million (Q4 2025), and $97.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 1.79 Bn |
| 10 | Cresco Labs | 295.09 Mn | 230.98 Mn | 86.95 Mn | 137.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 98.17 Mn |
| Dec 31, 2025 | 100.18 Mn |
| Sep 30, 2025 | 97.37 Mn |
| Jun 30, 2025 | 101.32 Mn |
| Mar 31, 2025 | 113.20 Mn |
| Dec 31, 2024 | 94.34 Mn |
| Sep 30, 2024 | 158.57 Mn |
| Jun 30, 2024 | 136.88 Mn |
| Mar 31, 2024 | 209.15 Mn |
| Dec 31, 2023 | 200.24 Mn |
| Sep 30, 2023 | 260.88 Mn |
| Jun 30, 2023 | 237.65 Mn |
| Mar 31, 2023 | 272.55 Mn |
| Dec 31, 2022 | 255.87 Mn |
| Sep 30, 2022 | 270.56 Mn |
| Jun 30, 2022 | 228.22 Mn |
| Mar 31, 2022 | 331.19 Mn |
| Dec 31, 2021 | 288.39 Mn |
| Sep 30, 2021 | 209.24 Mn |
| Mar 31, 2021 | 276.61 Mn |